Risk-Adapted Treatment of Aggressive B-Cell Lymphomas: Application of Novel Agents

Clinical Management of Novel Therapies for Hematologic Malignancies: Risk-Adapted Treatment of Aggressive B-Cell Lymphomas: Application of Novel Agents

This CME/CE/CPE certified activity is jointly provided by:

Harborside Medical Education

Harborside Medical Education (HSME), a division of Harborside, is committed to advancing care for people with cancer and improving patient outcomes through professional continuing education (CE) activities in oncology that address practice gaps and promote change in learners’ knowledge, competence and performance in both community and academic practice settings.

Release date: July 16, 2018

Expiration date: July 16, 2019

Annenberg Center for Health Sciences at Eisenhower
39000 Bob Hope Drive, Dinah Shore Bldg.
Rancho Mirage, CA 92270
Voice: 760-773-4500
Fax: 760-773-4513
E-mail: contactce@annenberg.net

Estimated time to complete activity: 1.25 hours

Journal of the Advanced Practitioner in Oncology

94 North Woodhull Road
Huntington, NY 11743
Voice: 631-692-0800
Fax: 631-692-0805
E-mail: editor@advancedpractitioner.com

This activity is supported by independent educational grants from Amgen, AstraZeneca, Celgene Corporation, Incyte Corporation, Merck Sharp & Dohme Corp., Takeda Oncology, Pharmacyclics LLC, an AbbVie Company, and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC.

Intended Audience

The activity’s target audience will consist of nurse practitioners, physician assistants, oncology pharmacists, clinical nurse specialists, medical and hematologic oncologists, and other clinicians who care for people with cancer.

Learning Objectives

After completing this educational activity, participants should be able to:

Diffuse Large B-Cell Lymphoma (DLBCL)

  • Describe the current treatments for early stage DLBCL
  • Describe the current treatments for relapsed/refractory DLBCL
  • Discuss the emerging therapies, their potential adverse events, and the associated clinical trials underway for DLBCL
  • Describe appropriate patient selection criteria for CAR-T therapy
  • Recall the strategies to mitigate for the potential of cytokine release syndrome and other serious side effects with CAR-T therapy

Mantle Cell Leukemia (MCL)

  • Describe the latest information on risk stratification of patients with MCL
  • Identify appropriate usage of new agents in the treatment of MCL
  • Describe how to best manage treatment side effects for patients with MCL

Continuing Education

Statement of Credit—Participants who successfully complete this activity (including the submission of the posttest and evaluation form) will receive a statement of credit.

Physicians. This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Annenberg Center for Health Sciences at Eisenhower and Harborside Medical Education. The Annenberg Center is accredited by the ACCME to provide continuing medical education for physicians.

The Annenberg Center for Health Sciences at Eisenhower designates this enduring activity for a maximum of 1.25 AMA PRA Category 1 Credits. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses. Annenberg Center for Health Sciences is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.

A maximum of 1.25 contact hours may be earned for successful completion of this activity.

Provider approved by the California Board of Registered Nursing, Provider No. 13664, for 1.25 contact hours.

Pharmacists. The Annenberg Center for Health Sciences at Eisenhower is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This program has been assigned ACPE Universal Program #0797-9999-18-078-H01-P. This program is designated for up to 1.25 contact hours (0.125 CEUs) of continuing pharmacy education credit.

Financial Disclosures

All individuals in positions to control the content of this program (e.g., planners, faculty, content reviewers) are expected to disclose all financial relationships with commercial interests that may have a direct bearing on the subject matter of this continuing education activity. The Annenberg Center for Health Sciences at Eisenhower has identified and resolved all conflicts of interest in accordance with the Annenberg Center for Health Sciences at Eisenhower policies and procedures. Participants have the responsibility to assess the impact (if any) of the disclosed information on the educational value of the activity.

Disclosures

FACULTY

Ms. Kurtin has received served as a consultant for AbbVie, Celgene, Genentech, and Pharmacyclics.

Ms. Goodrich has served on the speakers’ bureau for Gilead.

Dr. Kiel has served on speakers’ bureaus for Celgene, Genentech, Gilead, and Takeda.

Ms. Ridgeway has served on the speakers’ bureau for AbbVie and Pharmacyclics.

Ms. Rogers has served on advisory boards for Gilead, Merck, and Takeda; on speakers’ bureaus for Bristol-Myers Squibb, Genentech, Seattle Genetics, and Teva Pharmaceuticals.

ANNENBERG CENTER FOR HEALTH SCIENCES AT EISENHOWER

Charles Willis, Director, Continuing Education, consults for Pfizer Inc.; all other staff at the Annenberg Center for Health Sciences at Eisenhower have no relevant commercial relationships to disclose.

CONTENT REVIEWERS

Moshe C. Ornstein, MD, MA, Cleveland Clinic Taussig Cancer Institute (Reviewer) has served as a consultant for Pfizer and Eisai.

NURSE PLANNER

Dorothy Caputo, MA, BSN, RN, EduPro Resources, LLC, has no potential conflicts of interest to disclose.

PLANNERS

Harborside and Harborside Medical Education staff have no potential conflicts of interest to disclose.

Disclaimer

This activity has been designed to provide continuing education that is focused on specific objectives. In selecting educational activities, clinicians should pay special attention to the relevance of those objectives and the application to their particular needs. The intent of all Annenberg Center for Health Sciences at Eisenhower educational opportunities is to provide learning that will improve patient care. Clinicians are encouraged to reflect on this activity and its applicability to their own patient population. The opinions expressed in this activity are those of the faculty and reviewers and do not represent an endorsement by Annenberg Center for Health Sciences at Eisenhower of any specific therapeutics or approaches to diagnosis or patient management.

Product Disclosure

This educational activity may contain discussion of published as well as investigational uses of agents that are not approved by the U.S. Food and Drug Administration. For additional information about approved uses, including approved indications, contraindications, and warnings, please refer to the prescribing information for each product.

How to Earn Credit

Learners must complete the learning assessment and evaluation.

Statement of Credit: Participants who successfully complete this activity (including scoring of a minimum of 70% on the learning assessment) and complete and submit the evaluation form will be able to download a statement of credit.

Course summary
Available credit: 
  • 1.25 ACPE
  • 1.25 AMA PRA Category 1 Credit(s)™
  • 1.25 Attendance
  • 1.25 CA-BRN
  • 1.25 ANCC
Course opens: 
07/16/2018
Course expires: 
07/16/2019
Cost:
$0.00
Rating: 
0

Available Credit

  • 1.25 ACPE
  • 1.25 AMA PRA Category 1 Credit(s)™
  • 1.25 Attendance
  • 1.25 CA-BRN
  • 1.25 ANCC

Accreditation Period

Course opens: 
07/16/2018
Course expires: 
07/16/2019

Price

Cost:
$0.00
Please login or register to take this course.